[1] Stanley JR. Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion. Adv Immunol,1993,53:291-325. [2] Thoma-Uszynski S, Uter W, Schwietzke S, et al. BP230- and BP180-specific auto-antibodies in bullous pemphigoid. J Invest Dermatol,2004,122(6):1413-1422. [3] Sitaru C, Schmidt E, Petermann S, et al. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol,2002,118(4):664-671. [4] Kobayashi M, Amagai M, Kuroda-Kinoshita K, et al. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci, 2002, 30(3):224-232. [5] Sakuma-Oyama Y, Powell AM, Oyama N, et al. Evaluation of a BP180-NC16a enzyme-linked immunosorbent assay in the initial diagnosis of bullous pemphigoid. Br J Dermatol, 2004,151(1):126-131. [6] Feng S, Lin L, Jin P, et al. Role of BP180NC16a-enzyme-linked immunosorbent assay (ELISA) in the diagnosis of bullous pemphigoid in China. Int J Dermatol, 2008,47(1):24-28. [7] Ghohestani RF, Cozzani E, Kanitakis J, et al. BPAg2 antibodies are present at lower levels than BPAg1 antibodies in serum from patients with bullous pemphigoid. Eur J Dermatol,1996,6(7):491-494. [8] Pas HH,de Jong MCJM, Jonkman MF, et al. Bullous pemphigoid: serum antibody titre and antigen specificity. Exp Dermatol,1995, 4(6):372-376. |